Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrel...
Saved in:
| Main Authors: | Giang H. Ta, Max K. Leong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1496630/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01) -
Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis
by: Yu Wang, et al.
Published: (2024-08-01) -
Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Salivary Polymerase Chain Reaction: A Prospective Cohort Study
by: Chun-Han Tseng, et al.
Published: (2024-12-01) -
Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01) -
Paxlovid for the treatment of severe or critical COVID-19 in children
by: Linjuan Xiang, et al.
Published: (2025-07-01)